Thalidomide treatment of relapsed multiple myeloma patients and changes in circulating VEGF and bFGF

Br J Haematol. 2002 Oct;119(1):275. doi: 10.1046/j.1365-2141.2002.37694.x.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Endothelial Growth Factors / blood
  • Fibroblast Growth Factor 2 / blood
  • Humans
  • Intercellular Signaling Peptides and Proteins / blood
  • Lymphokines / blood
  • Multiple Myeloma / drug therapy*
  • Recurrence
  • Thalidomide / therapeutic use*
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors

Substances

  • Angiogenesis Inhibitors
  • Endothelial Growth Factors
  • Intercellular Signaling Peptides and Proteins
  • Lymphokines
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors
  • Fibroblast Growth Factor 2
  • Thalidomide